Original ArticlePerformance of the Osteoporosis Self-assessment Screening Tool for Osteoporosis in American Men
Section snippets
PATIENTS AND METHODS
We used data from 2 identical cross-sectional studies7, 8 conducted among patients enrolled in a pulmonary clinic (evaluated from January-May 2001) and a rheumatology clinic (evaluated November 2001-March 2002) at a single Veterans Affairs medical center. The studies evaluated the usefulness of screening methods to predict osteoporosis as defined by DXA. Only patients who had not previously undergone DXA were eligible to participate. After signing an informed consent form, the patients filled
RESULTS
A total of 181 men (124 white, 54 black, 3 other) filled out a questionnaire and underwent DXA. Characteristics of the study patients are listed in Table 1. The mean age was 64.3 years, and the mean weight was 91.2 kg. The OST risk index varied between −5 and 19. The percent distribution of the patients according to their OST risk index (mean index, 5±5) is shown in Figure 1.
By defining osteoporosis as a T score of −2.5 or less in the spine, total hip, or femoral neck, an OST cutoff of 3
DISCUSSION
In Asian women, the OST has performed as well as or better than more complicated osteoporosis screening tools (Simple Calculated Osteoporosis Risk Estimation [SCORE] and Osteoporosis Risk Assessment Instrument [ORAI]).1, 2, 3, 4, 5 In Asian women,5 the sensitivity was 91% and the specificity 45%, with an AUC of 0.790. Validation of the OST in white women6 showed similar results among the various screening tools, but the OST was the easiest to administer. The simplicity of the tool makes it more
CONCLUSION
The OST was valid in male veterans from 2 subspecialty clinics. The OST appears to be an excellent method to identify men at high and low risk of osteoporosis, as defined by DXA.
Acknowledgments
We acknowledge the help of Philip D. Ross, PhD, of Merck & Co, Inc, who suggested that we test the OST in men.
REFERENCES (13)
- et al.
Performance of risk indices for identifying low bone density in postmenopausal women
Mayo Clin Proc
(2002) - et al.
Utility of heel ultrasound bone density in men
J Clin Densitom
(2001) - et al.
Validation of the simple calculated osteoporosis risk estimation (SCORE) for patient selection for bone densitometry
Osteoporos Int
(1999) - et al.
Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density
Am J Manag Care
(1998) - et al.
Interest of a prescreening questionnaire to reduce the cost of bone densitometry
Osteoporos Int
(2002) - et al.
Development of a simple self-administered questionnaire useful for predicting low bone mass in men [abstract]
J Bone Miner Res
(2000)
Cited by (89)
Consensus document on osteoporosis in males
2018, Endocrinologia, Diabetes y NutricionUtility of Osteoporosis Self-Assessment Tool as a Screening Tool for Osteoporosis in Irish Men and Women: Results of the DXA-HIP Project
2021, Journal of Clinical DensitometryCitation Excerpt :Men represent a much small proportion of our study population, particularly those taking osteoporosis medication at the time of their first DXA scan. Although not as large as some, we have greater numbers and a greater spectrum of ages than others (10,19,22,23,26). We used a DXA T-score as the standard for assessing the sensitivity and specificity of the OSTi, but the selection of a T-score threshold has been described as ‘too easy’ and is not without its flaws (45).
Machine Learning Can Improve Clinical Detection of Low BMD: The DXA-HIP Study
2021, Journal of Clinical DensitometryWho should be screened for osteoporosis?
2020, Marcus and Feldman’s OsteoporosisOsteoporosis in men: What is similar and what is different?
2020, Marcus and Feldman’s Osteoporosis
This study was sponsored by an unrestricted grant from Merck & Co, Inc.
- 1
Dr Tran is now with the Kaiser Permanente Colorado Region, Denver.
- 2
Dr Adler has received research grants from Merck & Co, Inc, Eli Lilly and Company, Novartis, and Procter & Gamble and is a speaker or consultant for Merck & Co, Inc, Eli Lilly and Company, Novartis, and Procter & Gamble.